This study aims to comprehensively explore the interplay between estrogen receptor (ER) signaling and the PI3K/AKT/mTOR pathway in breast cancer, emphasizing its role in tumor progression, endocrine resistance, and therapeutic targeting. This evidence concerns the gene ESR1 and breast carcinoma.